Photobiomodulation for Dry AMD

Clinical Report: Photobiomodulation for Dry AMD

Overview

Photobiomodulation (PBM) is an FDA-authorized treatment for dry age-related macular degeneration (AMD) that improves visual acuity in patients. The LIGHTSITE III trial demonstrated significant visual improvements over 24 months, establishing PBM as a viable option for early- and intermediate-stage dry AMD.

Background

Dry age-related macular degeneration (AMD) is a leading cause of vision loss among older adults, making effective treatment options critical. Photobiomodulation (PBM) utilizes low-intensity light to enhance cellular function in retinal tissues, potentially reversing some effects of AMD. The recent FDA authorization of the Valeda Light Delivery System marks a significant advancement in the management of this condition.

Data Highlights

Study	Outcome	Duration
LIGHTSITE III	Mean visual acuity improvement of approximately 1 line (ETDRS)	24 months

Key Findings

PBM improves mitochondrial activity, reducing oxidative stress and inflammation in retinal cells.
Patients with BCVA of 20/32 to 20/70 showed significant visual improvements after PBM treatment.
The treatment involves 9 sessions over 3 to 5 weeks, repeated every 4 months.
Documentation and coding for PBM are essential for reimbursement, with specific ICD-10 codes required.
Category III CPT code 0936T will be effective from January 1, 2025, for billing PBM sessions.

Clinical Implications

Healthcare providers should be aware of the documentation and coding requirements for PBM to ensure proper reimbursement. As PBM is the first treatment shown to improve vision loss in dry AMD, it represents a significant advancement in patient care for this condition.

Conclusion

Photobiomodulation offers a promising treatment option for patients with dry AMD, with evidence supporting its efficacy and safety. Ongoing education on coding and coverage will be crucial for its successful implementation in clinical practice.

PentaVision

Ophthalmic Professional